Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Monoamine abnormalities in the SAPAP3 knockout model of obsessive-compulsive disorder-related behaviour.

Wood J, LaPalombara Z, Ahmari SE.

Philos Trans R Soc Lond B Biol Sci. 2018 Mar 19;373(1742). pii: 20170023. doi: 10.1098/rstb.2017.0023.

PMID:
29352023
2.

Prefrontal cortex activation during neuropsychological tasks might predict response to pharmacotherapy in patients with obsessive-compulsive disorder.

Takeda T, Sumitani S, Hamatani S, Yokose Y, Shikata M, Ohmori T.

Neuropsychiatr Dis Treat. 2017 Feb 23;13:577-583. doi: 10.2147/NDT.S127752. eCollection 2017.

3.

Ziprasidone Augmentation in an Adolescent with Obsessive Compulsive Disorder: A Case Report.

Demirkaya SK, Alyanak B.

Psychopharmacol Bull. 2016 Mar 1;46(1):73-76.

4.

Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention.

Wheaton MG, Carpenter JK, Kalanthroff E, Foa EB, Simpson HB.

Psychother Psychosom. 2016;85(5):314-6. doi: 10.1159/000445356. Epub 2016 Aug 12. No abstract available.

5.

Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics.

Kazdoba TM, Leach PT, Yang M, Silverman JL, Solomon M, Crawley JN.

Curr Top Behav Neurosci. 2016;28:1-52. doi: 10.1007/7854_2015_5003. Review.

6.

A Framework for Understanding the Emerging Role of Corticolimbic-Ventral Striatal Networks in OCD-Associated Repetitive Behaviors.

Wood J, Ahmari SE.

Front Syst Neurosci. 2015 Dec 17;9:171. doi: 10.3389/fnsys.2015.00171. eCollection 2015. Review.

7.

Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.

McLean CP, Zandberg LJ, Van Meter PE, Carpenter JK, Simpson HB, Foa EB.

J Clin Psychiatry. 2015 Dec;76(12):1653-7. doi: 10.4088/JCP.14m09513.

8.

Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.

Pittenger C, Bloch MH, Wasylink S, Billingslea E, Simpson R, Jakubovski E, Kelmendi B, Sanacora G, Coric V.

J Clin Psychiatry. 2015 Aug;76(8):1075-84. doi: 10.4088/JCP.14m09123.

9.

Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?

Wheaton MG, Rosenfield D, Foa EB, Simpson HB.

J Consult Clin Psychol. 2015 Oct;83(5):926-937. doi: 10.1037/ccp0000025. Epub 2015 May 25.

10.
11.

Assessment and management of treatment-refractory obsessive-compulsive disorder in children.

Bloch MH, Storch EA.

J Am Acad Child Adolesc Psychiatry. 2015 Apr;54(4):251-62. doi: 10.1016/j.jaac.2015.01.011. Epub 2015 Jan 30. Review.

12.

Aripiprazole versus quetiapine in treatment-resistant obsessive-compulsive disorder: a double-blind clinical trial.

Shoja Shafti S, Kaviani H.

Ther Adv Psychopharmacol. 2015 Feb;5(1):32-7. doi: 10.1177/2045125314560739.

13.

Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.

Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J.

BMC Psychiatry. 2014 Nov 29;14:317. doi: 10.1186/s12888-014-0317-5. Review.

14.

Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.

Foa EB, Simpson HB, Rosenfield D, Liebowitz MR, Cahill SP, Huppert JD, Bender J Jr, McLean CP, Maher MJ, Campeas R, Hahn CG, Imms P, Pinto A, Powers MB, Rodriguez CI, Van Meter PE, Vermes D, Williams MT.

J Clin Psychiatry. 2015 Apr;76(4):440-6. doi: 10.4088/JCP.14m09044.

15.

Management of obsessive-compulsive disorder.

Seibell PJ, Hollander E.

F1000Prime Rep. 2014 Aug 1;6:68. doi: 10.12703/P6-68. eCollection 2014. Review.

16.

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University, Antony MM, Bouchard S, Brunet A, Flament M, Grigoriadis S, Mendlowitz S, O'Connor K, Rabheru K, Richter PM, Robichaud M, Walker JR.

BMC Psychiatry. 2014;14 Suppl 1:S1. doi: 10.1186/1471-244X-14-S1-S1. Epub 2014 Jul 2. Review.

17.

Dopaminergic control of cognitive flexibility in humans and animals.

Klanker M, Feenstra M, Denys D.

Front Neurosci. 2013 Nov 5;7:201. doi: 10.3389/fnins.2013.00201. Review.

18.

Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J Jr, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R.

JAMA Psychiatry. 2013 Nov;70(11):1190-9. doi: 10.1001/jamapsychiatry.2013.1932.

19.

Pharmacotherapy response and regional cerebral blood flow characteristics in patients with obsessive-compulsive disorder.

Wen SL, Cheng MH, Cheng MF, Yue JH, Wang H.

Behav Brain Funct. 2013 Jul 30;9:31. doi: 10.1186/1744-9081-9-31.

20.

Evidence-based pharmacotherapy for pediatric obsessive-compulsive disorder and chronic tic disorders.

De Nadai AS, Storch EA, McGuire JF, Lewin AB, Murphy TK.

J Cent Nerv Syst Dis. 2011 Jun 1;3:125-42. doi: 10.4137/JCNSD.S6616. Print 2011.

Supplemental Content

Support Center